Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches

Lung Cancer

Volumn 106, Issue , 2017, Pages 70-75

  Remon, J ^a   Pardo, N ^a   Martinez Marti A ^a   Cedres S ^a   Navarro, A ^a   Martinez de Castro, A M ^a   Felip, E ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

First line; Immunotherapy; Nivolumab; Non small cell lung cancer; Pembrolizumab

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; HUMAN; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 85012013235     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.02.002     Document Type: Review

References (42)

1. [1] Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461, 10.1016/j.ccell.2015.03.001.
2. [2] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264, 10.1038/nrc3239.
3. [3] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674, 10.1016/j.cell.2011.02.013.
4. [4] Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M.C., Aerts, J.G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C.T., Lestini, B., Spigel, D.R., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135, 10.1056/NEJMoa1504627.
5. [5] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M.A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D.E., Gettinger, S.N., Rudin, C.M., Rizvi, N., Crinò, L., Blumenschein, G.R., Antonia, S.J., Dorange, C., Harbison, C.T., Graf Finckenstein, F., Brahmer, J.R., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med., 2015, 10.1056/NEJMoa1507643.
6. [6] Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C.D., Ahn, M.-J., Majem, M., Fidler, M.J., de Castro, G., Garrido, M., Lubiniecki, G.M., Shentu, Y., Im, E., Dolled-Filhart, M., Garon, E.B., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550, 10.1016/S0140-6736(15)01281-7.
7. [7] Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S.M., Hida, T., Kowalski, D.M., Dols, M.C., Cortinovis, D.L., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O.A., De Marinis, F., Turna, H., Lee, J.-S., Ballinger, M., Kowanetz, M., He, P., Chen, D.S., Sandler, A., Gandara, D.R., OAK Study Group, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2016, 10.1016/s0140-6736(16)32517-x.
8. [8] R.N. Pillai, M. Behera, T.K. Owonikoko, A.O. Kamphorst, S. Pakkala, C.P. Belani, F.R. Khuri, R. Ahmed, S.S. Ramalingam, Evalaution of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cacner. J. Thorac. Oncol. 2016. 11 (10S): OA03.06 (n.d.).
9. [9] M. Garassino, J. Vansteenkiste, J.H. Kim, H. Lena, J. Mazières, J. Powderly, P. Dennis, Y. Huang, C. Wadsworth, N. Rizvi, Durvalumab in ≥3rd-line locally advanced or metastatic, EGFR/ALK wild-type NSCLC: results from the Phase 2 ATLANTIC study, J. Thorac. Oncol. 2016; PL04a.03. (n.d.).
10. [10] Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M.G., Kerr, K., Popat, S., Reck, M., Senan, S., Simo, G.V., Vansteenkiste, J., Peters, S., ESMO guidelines committee, metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 (2016), v1–v27, 10.1093/annonc/mdw326.
11. [11] Midha, A., Dearden, S., McCormack, R., EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am. J. Cancer. Res. 5 (2015), 2892–2911.
12. [12] Dearden, S., Stevens, J., Wu, Y.-L., Blowers, D., Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann. Oncol. 24 (2013), 2371–2376, 10.1093/annonc/mdt205.
13. [13] Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Ahn, M.-J., Felip, E., Lee, J.-S., Hellmann, M.D., Hamid, O., Goldman, J.W., Soria, J.-C., Dolled-Filhart, M., Rutledge, R.Z., Zhang, J., Lunceford, J.K., Rangwala, R., Lubiniecki, G.M., Roach, C., Emancipator, K., Gandhi, L., KEYNOTE-001 investigators, pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028, 10.1056/NEJMoa1501824.
14. [14] Ramalingam, S., Hui, R., Gandhi, L., Carcereny, E., Felip, E., Ahn, M.-J., Eder, J.P., Balmanoukian, A.S., Leighl, N., Aggarwal, C., Horn, L., Patnaik, A., Middleton, G.W., Gubens, M., Hellmann, M., Soria, J.-C., Lubiniecki, G.M., Zhang, J., Piperdi, B., Garon, E.B., P2.39: long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab: track: immunotherapy. J. Thorac. Oncol. 11 (2016), S241–S242, 10.1016/j.jtho.2016.08.110.
15. [15] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M., Shentu, Y., Rangwala, R., Brahmer, J.R., KEYNOTE-024 investigators, pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375 (2016), 1823–1833, 10.1056/NEJMoa1606774.
16. [16] J. Brahmer, D. Rodriguez-Abreu, A.G. Robinson, R. Hui, T. Csoszi, A. Fulop, M. Gottfried, N. Peled, A. Tafreshi, et al. Health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024, J. Clin. Oncol. 34, 2016 (Suppl; Abstr 7153). (n.d.).
17. [17] Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J.S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K.P., Gandara, D., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26 (2008), 3543–3551, 10.1200/JCO.2007.15.0375.
18. [18] Gettinger, S., Rizvi, N.A., Chow, L.Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D.E., Shepherd, F.A., Antonia, S., Goldman, J.W., Juergens, R.A., Laurie, S.A., Nathan, F.E., Shen, Y., Harbison, C.T., Hellmann, M.D., Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 34 (2016), 2980–2987, 10.1200/JCO.2016.66.9929.
19. [19] M. Socinski, CheckMate 026: A phase 3 trialof nivolumab vs investigator's choice of platinumn based doublet chemotherapy as first-line therapy for stage IV/recurrent programmed death lignad 1 positive NSCLC, ESMO 2016, LBA7. (n.d.).
20. [20] Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., Chaput, N., Eggermont, A.M., Marabelle, A., Soria, J.-C., Ferté, C., Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin. Cancer Res., 2016, 10.1158/1078-0432.ccr-16-1741 CCR-16-1741.
21. [21] M. Garassino, N. Rizvi, b. Besse, P.A. Jänne, D. Christoph, S. Peters, C. Toh, T. Kurata et al, Atezolizumab as 1L therapy for advanced NSCLC in PD-L1–selected patients: updated ORR, PFS and OS data from the BIRCH study, J. Thorac. Oncol. 2016; Abstract 4799. (n.d.).
22. [22] G. Jerusalem, F.L. Chen, D. Spigel, N. Iannotti, E.F. McClay, C.H. Redfem, J. Bennouna, M. Taylor et al. JAVELIN Solid tumor: safety and clinical activity of avelumab (Anti-PD-L1) as first-line treatment in patients with advanced NSCLC, J. Thorac. Oncol. 2016; Abstract 3717. (n.d.).
23. [23] Antonia, S.J., Kim, S.-W., Spira, A.I., Ahn, M.-J., Ou, S.-H.I., Stjepanovic, N., Fasolo, A., Jager, D., Ott, P.A., Wainberg, Z.A., Wakelee, H.A., Goldman, J.W., Kurland, J., Rebelatto, M.C., Yao, W., Gupta, A.K., Blake-Haskins, J.A., Segal, N.H., Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non-small-cell lung cancer. ASCO Meeting, 34, 2016, 9029.
24. [24] Liu, W.M., Fowler, D.W., Smith, P., Dalgleish, A.G., Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br. J. Cancer 102 (2010), 115–123, 10.1038/sj.bjc.6605465.
25. [25] Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S.K., Konishi, I., Mandai, M., Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75 (2015), 5034–5045, 10.1158/0008-5472.CAN-14-3098.
26. [26] Zhang, P., Ma, Y., Lv, C., Huang, M., Li, M., Dong, B., Liu, X., An, G., Zhang, W., Zhang, J., Zhang, L., Zhang, S., Yang, Y., The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy. Cancer Sci., 2016, 10.1111/cas.13072.
27. [27] Rizvi, N.A., Hellmann, M.D., Brahmer, J.R., Juergens, R.A., Borghaei, H., Gettinger, S., Chow, L.Q., Gerber, D.E., Laurie, S.A., Goldman, J.W., Shepherd, F.A., Chen, A.C., Shen, Y., Nathan, F.E., Harbison, C.T., Antonia, S., Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 34 (2016), 2969–2979, 10.1200/JCO.2016.66.9861.
28. [28] Kanda, S., Goto, K., Shiraishi, H., Kubo, E., Tanaka, A., Utsumi, H., Sunami, K., Kitazono, S., Mizugaki, H., Horinouchi, H., Fujiwara, Y., Nokihara, H., Yamamoto, N., Hozumi, H., Tamura, T., Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Ann. Oncol., 2016, 10.1093/annonc/mdw416.
29. [29] Gadgeel, S.M., Stevenson, J., Langer, C.J., Gandhi, L., Borghaei, H., Patnaik, A., Villaruz, L.C., Gubens, M.A., Hauke, R.J., Yang, J.C.-H., Sequist, L.V., Bachman, R.D., Ge, J.Y., Raftopoulos, H., Papadimitrakopoulou, V., Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. ASCO Meeting, 34, 2016, 9016.
30. [30] G.Giaccone, D. Camidge, S. Liu, J. Powderly, S. hodi, S. Gettinger, et al, Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a phase Ib study, J. Thorac. Oncol. 2015; 10 (suppls 2) P247 (n.d.).
31. [31] Langer, C.J., Gadgeel, S.M., Borghaei, H., Papadimitrakopoulou, V.A., Patnaik, A., Powell, S.F., Gentzler, R.D., Martins, R.G., Stevenson, J.P., Jalal, S.I., Panwalkar, A., Yang, J.C.-H., Gubens, M., Sequist, L.V., Awad, M.M., Fiore, J., Ge, Y., Raftopoulos, H., Gandhi, L., KEYNOTE-021 investigators, carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17 (2016), 1497–1508, 10.1016/S1470-2045(16)30498-3.
32. [32] Patel, J.D., Socinski, M.A., Garon, E.B., Reynolds, C.H., Spigel, D.R., Olsen, M.R., Hermann, R.C., Jotte, R.M., Beck, T., Richards, D.A., Guba, S.C., Liu, J., Frimodt, M.B., John, W.J., Obasaju, C.K., Pennella, E.J., Bonomi, P., Govindan, R., PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 31 (2013), 4349–4357.
33. [33] Zatloukal, P., Heo, D.S., Park, K., Kang, J., Butts, C., Bradford, D., Graziano, S., Huang, B., Healey, D., Randomized phase II clinical trial comparing tremelimumab (CP-675 206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). ASCO Meeting, 27, 2009, 8071.
34. [34] Lynch, T.J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., Reck, M., Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30 (2012), 2046–2054, 10.1200/JCO.2011.38.4032.
35. [35] Curran, M.A., Montalvo, W., Yagita, H., Allison, J.P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 4275–4280, 10.1073/pnas.0915174107.
36. [36] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P.F., Hill, A., Wagstaff, J., Carlino, M.S., Haanen, J.B., Maio, M., Marquez-Rodas, I., McArthur, G.A., Ascierto, P.A., Long, G.V., Callahan, M.K., Postow, M.A., Grossmann, K., Sznol, M., Dreno, B., Bastholt, L., Yang, A., Rollin, L.M., Horak, C., Hodi, F.S., Wolchok, J.D., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34, 10.1056/NEJMoa1504030.
37. [37] Antonia, S.J., López-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P., Jäger, D., Pietanza, M.C., Le, D.T., de Braud, F., Morse, M.A., Ascierto, P.A., Horn, L., Amin, A., Pillai, R.N., Evans, J., Chau, I., Bono, P., Atmaca, A., Sharma, P., Harbison, C.T., Lin, C.-S., Christensen, O., Calvo, E., Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17 (2016), 883–895, 10.1016/S1470-2045(16)30098-5.
38. [38] Patnaik, A., Socinski, M.A., Gubens, M.A., Gandhi, L., Stevenson, J., Bachman, R.D., Bourque, J., Yang Ge, J., Im, E., Gadgeel, S.M., Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. ASCO Meeting., 33, 2015, 8011.
39. [39] Hellmann, M.D., Rizvi, N.A., Goldman, J.W., Gettinger, S.N., Borghaei, H., Brahmer, J.R., Ready, N.E., Gerber, D.E., Chow, L.Q., Juergens, R.A., Shepherd, F.A., Laurie, S.A., Geese, W.J., Agrawal, S., Young, T.C., Li, X., Antonia, S.J., Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol., 2016, 10.1016/s1470-2045(16)30624-6.
40. [40] Antonia, S., Goldberg, S.B., Balmanoukian, A., Chaft, J.E., Sanborn, R.E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J.J., Rizvi, N.A., Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 17 (2016), 299–308, 10.1016/S1470-2045(15)00544-6.
41. [41] Cherny, N., Sullivan, R., Torode, J., Saar, M., Eniu, A., ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann. Oncol. 27 (2016), 1423–1443, 10.1093/annonc/mdw213.
42. [42] D. Spigel, A. Schrock, D. Fabrizio, G.M. Frampton, J. Sun, J. He, K. Gowen, et al. Total mutation burden (TMB) in lung cancer and relationship with response to PD-1/PD-L1 targeted therapies, J. Clin. Oncol. 34, 2016 (Suppl; Abstr 9017). (n.d.).